SciSparc initiates patient recruitment for clinical trial with SCI-210

SciSparc announces the initiation of patient recruitment for its clinical trial in children suffering from autism spectrum disorder at Soroka Medical Center in Israel. The double-blind, randomized and placebo-controlled study will be performed using SciSparc’s proprietary SCI-210, a combination of cannabidiol and CannAmide, which is designed to alleviate ASD symptoms. SciSparc will enroll 60 subjects between the ages of five and 18, for 20 weeks, with the purpose of assessing how SCI-210 therapy compares to standard CBD treatment in managing symptoms of ASD. The Company’s goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals. The trial has three primary efficacy metrics: the Aberrant Behavior Checklist-Community parent questionnaire; the Clinical Global Impressions-Improvement performed by a clinician; and the effective therapeutic dose. The trial was designed in consultation with the National Autism Research Center, the leading research center for autism in Israel.